» Articles » PMID: 15223070

Tetrahydrobiopterin Rapidly Reduces the SOD Mimic Mn(III) Ortho-tetrakis(N-ethylpyridinium-2-yl)porphyrin

Overview
Date 2004 Jun 30
PMID 15223070
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Mn(III) ortho-tetrakis(N-ethylpyridinium-2-yl)porphyrin (Mn(III)TE-2-PyP(5+)) effectively scavenges reactive oxygen and nitrogen species in vitro, and protects in vivo, in different rodent models of oxidative stress injuries. Further, Mn(III)TE-2-PyP(5+) was shown to be readily reduced by cellular reductants such as ascorbic acid and glutathione. We now show that tetrahydrobiopterin (BH(4)) is also able to reduce the metal center. Under anaerobic conditions, in phosphate-buffered saline (pH 7.4) at 25 +/- 0.1 degrees C, reduction of Mn(III)TE-2-PyP(5+) occurs through two reaction steps with rate constants k(1) = 1.0 x 10(4) M(-1) s(-1) and k(2) = 1.5 x 10(3) M(-1) s(-1). We ascribe these steps to the formation of tetrahydrobiopterin radical (BH(4)(.+)) (k(1)) that then undergoes oxidation to 6,7-dihydro-8H-biopterin (k(2)), which upon rearrangement gives rise to 7,8-dihydrobiopterin (7,8-BH(2)). Under aerobic conditions, Mn(III)TE-2-PyP(5+) catalytically oxidizes BH(4). This is also true for its longer chain alkyl analog, Mn(III) ortho-tetrakis(N-n-octylpyridinium-2-yl)porphyrin. The reduced Mn(II) porphyrin cannot be oxidized by 7,8-BH(2) or by l-sepiapterin. The data are discussed with regard to the possible impact of the interaction of Mn(III)TE-2-PyP(5+) with BH(4) on endothelial cell proliferation and hence on tumor antiangiogenesis via inhibition of nitric oxide synthase.

Citing Articles

Targeting oxidative stress in disease: promise and limitations of antioxidant therapy.

Forman H, Zhang H Nat Rev Drug Discov. 2021; 20(9):689-709.

PMID: 34194012 PMC: 8243062. DOI: 10.1038/s41573-021-00233-1.


Thiol regulation by Mn porphyrins, commonly known as SOD mimics.

Batinic-Haberle I, Tome M Redox Biol. 2019; 25:101139.

PMID: 31126869 PMC: 6859569. DOI: 10.1016/j.redox.2019.101139.


Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury.

Batinic-Haberle I, Tovmasyan A, Spasojevic I Antioxid Redox Signal. 2018; 29(16):1691-1724.

PMID: 29926755 PMC: 6207162. DOI: 10.1089/ars.2017.7453.


A comprehensive evaluation of catalase-like activity of different classes of redox-active therapeutics.

Tovmasyan A, Maia C, Weitner T, Carballal S, Sampaio R, Lieb D Free Radic Biol Med. 2015; 86:308-21.

PMID: 26026699 PMC: 4554972. DOI: 10.1016/j.freeradbiomed.2015.05.018.


An educational overview of the chemistry, biochemistry and therapeutic aspects of Mn porphyrins--From superoxide dismutation to H2O2-driven pathways.

Batinic-Haberle I, Tovmasyan A, Spasojevic I Redox Biol. 2015; 5:43-65.

PMID: 25827425 PMC: 4392060. DOI: 10.1016/j.redox.2015.01.017.